Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal CancerCohort Study · 2016 · 182 citations
2. 2Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerLate-Phase Clinical Trial · 2008 · 3,209 citations
3. 3Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancerEarly-Phase Clinical Trial · 2017 · 97 citations
4. 4KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapyRetrospective Study · 2013 · 176 citations
5. 5Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal CancerEarly-Phase Clinical Trial · 2017 · 98 citations